对比增强超声与MRI评估腹外硬纤维瘤治疗反应的可行性研究
前瞻性纳入21例接受药物治疗的腹外硬纤维瘤成人患者,其中19例完成治疗前后评估,采用临床评估、MRI和对比增强超声(CEUS)评价疗效。临床改善率73.68%,MRI仅41.18%显示反应,按RECIST 1.1仅29.41%达部分缓解;MRI显示有反应者CEUS均持续强化且平均通过时间(MTT)显著缩短(p=0.047)。作者认为CEUS有潜力作为硬纤维瘤治疗反应评估工具,可实时反映病灶内微血管变化。
要点
- MRI显示有反应者CEUS均持续强化,且平均通过时间(MTT)显著缩短(p=0.047)。
- 按RECIST 1.1仅29.41%达部分缓解,MRI显示反应者占41.18%,临床改善者占73.68%。
- CEUS可实时反映病灶内微血管变化,作者认为其有潜力作为硬纤维瘤治疗反应评估工具。
核心结论
- CEUS有潜力作为硬纤维瘤的有效治疗反应评估工具,可提供病灶内微血管变化的实时信息。
研究设计与样本
- 前瞻性研究,2022年3月至2023年12月纳入21例接受药物治疗的腹外硬纤维瘤成人患者,其中19例完成治疗前后评估,联合临床评估、MRI与CEUS进行疗效评价,统计分析采用非参数检验。
关键影像表现/征象
- MRI显示有反应者,CEUS上均表现为持续强化。
- CEUS测得平均通过时间(MTT)显著缩短(p=0.047)。
- 临床改善者占73.68%,MRI显示反应者占41.18%,按RECIST 1.1达部分缓解者仅占29.41%。
诊断标准与关键数值
- 按RECIST 1.1标准,19例中29.41%达到部分缓解。
- MRI显示治疗反应者占41.18%。
- 临床改善(症状缓解)者占73.68%。
- CEUS平均通过时间(MTT)在治疗前后比较p=0.047。
临床应用与阅片要点
- 作者认为CEUS有潜力作为硬纤维瘤治疗反应评估工具,可实时反映病灶内微血管变化。
- 常规RECIST标准不足以评价硬纤维瘤的治疗反应。
- MRI是首选检查方式,但在可及性与一致性方面存在局限。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Desmoid Fibromatosis (DF) is a locally aggressive soft tissue tumor which was traditionally managed with surgical excision. However due to high rates of local recurrence and insights about its behavior, there is now a paradigm shift towards active surveillance and medical management. Imaging plays a crucial role in surveillance and treatment response; however, conventional RECIST criteria are not adequate for DF. MRI is the preferred modality but faces limitation in availability and uniformity. Although ultrasound (US) is not optimal for evaluation, contrast enhanced US has shown promising results in many solid tumors.
OBJECTIVES: To explore the role of Contrast Enhanced Ultrasound (CEUS) as a response assessment tool in DF.
MATERIALS AND METHODS: This was a prospective study conducted between March 2022 and December 2023 and included 21 adults with DF who received medical line of treatment. A combination of clinical evaluation for symptom relief, and imaging modalities using MRI and CEUS, were utilized for response assessment. Statistical analysis was performed using non parametric tests.
RESULTS: Out of 21, 19 patients underwent pre as well as post-treatment evaluation. Clinical improvement was reported by 73.68 % while MRI indicated response only in 41.18 %; whereas only 29.41 % met the criteria for partial response according to RECIST 1.1. All responders on MRI exhibited continued enhancement on CEUS with a significant decrease in Mean Transit Time (MTT, p = 0.047).
CONCLUSION: CEUS demonstrates potential as an effective treatment response tool in DF, providing real-time information of microvascular changes within the mass.
引用
- Dheeksha DS, Dhamija E, Mani K, et al. Contrast enhanced ultrasound versus MRI for response assessment of extra-abdominal desmoid Fibromatosis- A feasibility study. Eur J Radiol. 2025. PMID: 40187197. doi:10.1016/j.ejrad.2025.112071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。